{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:45Z","timestamp":1787003625181,"version":"build-2736575974"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science and Technology Research Project of Education Department of Liaoning Province","award":["No. L202048"],"award-info":[{"award-number":["No. L202048"]}]},{"name":"Youth Project of Basic Scientific Research Project of Education Department of Liaoning Province","award":["No. LJKQZ2021064"],"award-info":[{"award-number":["No. LJKQZ2021064"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-alcoholic steatohepatitis (NASH) is a hepatocyte inflammation based on hepatocellular steatosis, yet there is no effective drug treatment. Atherosclerosis (AS) is caused by lipid deposition in the endothelium, which can lead to various cardiovascular diseases. NASH and AS share common risk factors, and NASH can also elevate the risk of AS, causing a higher morbidity and mortality rate for atherosclerotic heart disease. Therefore, timely detection and diagnosis of NASH and AS are particularly important. In this study, differential gene expression analysis and weighted gene co-expression network analysis were performed on the AS (GSE100927) and NASH (GSE89632) datasets to obtain common crosstalk genes, respectively. Then, candidate Hub genes were screened using four topological algorithms and externally validated in the GSE43292 and GSE63067 datasets to obtain Hub genes. Furthermore, immune infiltration analysis and gene set variation analysis were performed on the Hub genes to explore the underlying mechanisms. The DGIbd database was used to screen candidate drugs for AS and NASH. Finally, a NASH model was constructed using free fatty acid-induced human L02 cells, an AS model was constructed using lipopolysaccharide-induced HUVECs, and a co-morbidity model was constructed using L02 cells and HUVECs to verify Hub gene expression. The result showed that a total of 113 genes common to both AS and NASH were identified as crosstalk genes, and enrichment analysis indicated that these genes were mainly involved in the regulation of immune and metabolism-related pathways. 28 candidate Hub genes were screened according to four topological algorithms, and CXCL9, IL2RB, and SPP1 were identified as Hub genes after in vitro experiments and external dataset validation. The ROC curves and SVM modeling demonstrated the good diagnostic efficacy of these three Hub genes. In addition, the Hub genes are strongly associated with immune cell infiltration, especially macrophages and \u03b3\u2013\u03b4 T cell infiltration. Finally, five potential therapeutic drugs were identified. has-miR-185 and hsa-miR-335 were closely related to AS and NASH. This study demonstrates that CXCL9, IL2RB, and SPP1 may serve as potential biomarkers for the diagnosis of the co-morbidity patterns of AS and NASH and as potential targets for drug therapy.<\/jats:p>","DOI":"10.1038\/s41598-024-66287-4","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T06:08:28Z","timestamp":1721110108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis"],"prefix":"10.1038","volume":"14","author":[{"given":"Xize","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changbin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"issue":"1","key":"66287_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1), 328\u2013357 (2018).","journal-title":"Hepatology"},{"issue":"1","key":"66287_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15(1), 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"66287_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5), 1547\u20131554 (2015).","journal-title":"Hepatology"},{"issue":"4","key":"66287_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh, S. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13(4), 643\u2013654 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"11","key":"66287_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrd.2016.188","volume":"15","author":"S Cassidy","year":"2016","unstructured":"Cassidy, S. & Syed, B. A. Nonalcoholic steatohepatitis (NASH) drugs market. Nat. Rev. Drug Discov. 15(11), 745\u2013746 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"66287_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong, R. J. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148(3), 547\u2013555 (2015).","journal-title":"Gastroenterology"},{"issue":"2","key":"66287_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/1753-0407.12970","volume":"12","author":"JK Beverly","year":"2020","unstructured":"Beverly, J. K. & Budoff, M. J. Atherosclerosis: Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation. J. Diabetes 12(2), 102\u2013104 (2020).","journal-title":"J. Diabetes"},{"issue":"9","key":"66287_CR8","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani, S. S. et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation 141(9), e139\u2013e596 (2020).","journal-title":"Circulation"},{"issue":"12","key":"66287_CR9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.121.055340","volume":"144","author":"G Bergstr\u00f6m","year":"2021","unstructured":"Bergstr\u00f6m, G. et al. Prevalence of subclinical coronary artery atherosclerosis in the general population. Circulation 144(12), 916\u2013929 (2021).","journal-title":"Circulation"},{"issue":"4","key":"66287_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4093\/dmj.2022.0198","volume":"46","author":"K Kim","year":"2022","unstructured":"Kim, K., Ginsberg, H. N. & Choi, S. H. New, novel lipid-lowering agents for reducing cardiovascular risk: Beyond statins. Diabetes Metab. J. 46(4), 517\u2013532 (2022).","journal-title":"Diabetes Metab. J."},{"issue":"15","key":"66287_CR11","doi-asserted-by":"publisher","first-page":"8229","DOI":"10.3390\/ijms23158229","volume":"23","author":"AM van den Hoek","year":"2022","unstructured":"van den Hoek, A. M. et al. Unraveling the transcriptional dynamics of NASH pathogenesis affecting atherosclerosis. Int. J. Mol. Sci. 23(15), 8229 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"66287_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111629","volume":"22","author":"J Guti\u00e9rrez-Cuevas","year":"2021","unstructured":"Guti\u00e9rrez-Cuevas, J., Santos, A. & Armendariz-Borunda, J. Pathophysiological molecular mechanisms of obesity: A link between MAFLD and NASH with cardiovascular diseases. Int. J. Mol. Sci. 22(21), 11629 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"66287_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.numecd.2016.06.011","volume":"26","author":"A Spahillari","year":"2016","unstructured":"Spahillari, A. et al. The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study. Nutr. Metab. Cardiovasc. Dis. 26(11), 1039\u20131047 (2016).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"2","key":"66287_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/cld.721","volume":"12","author":"CR Wong","year":"2018","unstructured":"Wong, C. R. & Lim, J. K. The association between nonalcoholic fatty liver disease and cardiovascular disease outcomes. Clin. Liver Dis. (Hoboken) 12(2), 39\u201344 (2018).","journal-title":"Clin. Liver Dis. (Hoboken)"},{"issue":"3","key":"66287_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0035-1562944","volume":"35","author":"E Vanni","year":"2015","unstructured":"Vanni, E., Marengo, A., Mezzabotta, L. & Bugianesi, E. Systemic complications of nonalcoholic fatty liver disease: When the liver is not an innocent bystander. Semin. Liver Dis. 35(3), 236\u2013249 (2015).","journal-title":"Semin. Liver Dis."},{"issue":"11","key":"66287_CR16","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3748\/wjg.v25.i11.1307","volume":"25","author":"JH Zhou","year":"2019","unstructured":"Zhou, J. H., Cai, J. J., She, Z. G. & Li, H. L. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J. Gastroenterol. 25(11), 1307\u20131326 (2019).","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"66287_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22292-y","volume":"8","author":"M Steenman","year":"2018","unstructured":"Steenman, M. et al. Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries. Sci. Rep. 8(1), 3940 (2018).","journal-title":"Sci. Rep."},{"issue":"5","key":"66287_CR18","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/hep.27695","volume":"61","author":"BM Arendt","year":"2015","unstructured":"Arendt, B. M. et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology 61(5), 1565\u20131578 (2015).","journal-title":"Hepatology"},{"key":"66287_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).","journal-title":"BMC Bioinform."},{"issue":"7","key":"66287_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43(7), e47 (2015).","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"66287_CR21","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman, B. T. et al. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50(W1), W216\u2013W221 (2022).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"66287_CR22","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51(D1), D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"66287_CR23","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk, D. et al. The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 49(D1), D605\u2013D612 (2021).","journal-title":"Nucleic Acids Res."},{"issue":"Suppl 4","key":"66287_CR24","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"CH Chin","year":"2014","unstructured":"Chin, C. H. et al. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8(Suppl 4), S11 (2014).","journal-title":"BMC Syst. Biol."},{"issue":"2","key":"66287_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12038-013-9310-2","volume":"38","author":"H Ayari","year":"2013","unstructured":"Ayari, H. & Bricca, G. Identification of two genes potentially associated in iron-heme homeostasis in human carotid plaque using microarray analysis. J. Biosci. 38(2), 311\u2013315 (2013).","journal-title":"J. Biosci."},{"issue":"2","key":"66287_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","volume":"18","author":"M Ahrens","year":"2013","unstructured":"Ahrens, M. et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab. 18(2), 296\u2013302 (2013).","journal-title":"Cell Metab."},{"key":"66287_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12, 77 (2011).","journal-title":"BMC Bioinform."},{"issue":"5","key":"66287_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12(5), 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"issue":"4","key":"66287_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/mps3040064","volume":"3","author":"K Hu","year":"2020","unstructured":"Hu, K. Become competent within one day in generating boxplots and violin plots for a novice without prior R experience. Methods Protoc. 3(4), 64 (2020).","journal-title":"Methods Protoc."},{"issue":"43","key":"66287_CR30","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102(43), 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66287_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"issue":"D1","key":"66287_CR32","doi-asserted-by":"publisher","first-page":"D222","DOI":"10.1093\/nar\/gkab1079","volume":"50","author":"HY Huang","year":"2022","unstructured":"Huang, H. Y. et al. miRTarBase update 2022: An informative resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 50(D1), D222\u2013D230 (2022).","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"66287_CR33","doi-asserted-by":"publisher","first-page":"bbac397","DOI":"10.1093\/bib\/bbac397","volume":"23","author":"L Huang","year":"2022","unstructured":"Huang, L., Zhang, L. & Chen, X. Updated review of advances in microRNAs and complex diseases: Experimental results, databases, webservers and data fusion. Brief. Bioinform. 23(6), bbac397 (2022).","journal-title":"Brief. Bioinform."},{"key":"66287_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117600","volume":"322","author":"J Li","year":"2023","unstructured":"Li, J. et al. Integrating transcriptomics and network pharmacology to reveal the mechanisms of total Rhizoma Coptidis alkaloids against nonalcoholic steatohepatitis. J. Ethnopharmacol. 322, 117600 (2023).","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"66287_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14131","volume":"75","author":"H Tutunchi","year":"2021","unstructured":"Tutunchi, H. et al. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study. Int. J. Clin. Pract. 75(6), e14131 (2021).","journal-title":"Int. J. Clin. Pract."},{"issue":"E-2","key":"66287_CR36","first-page":"4","volume":"67","author":"L Tureck\u00fd","year":"2021","unstructured":"Tureck\u00fd, L., Kup\u010dov\u00e1, V., Urfinov\u00e1, M., Repisk\u00fd, M. & Uhl\u00edkov\u00e1, E. Serum butyrylcholinesterase\/HDL-cholesterol ratio and atherogenic index of plasma in patients with fatty liver disease. Vnitr Lek. 67(E-2), 4\u20138 (2021).","journal-title":"Vnitr Lek."},{"issue":"16","key":"66287_CR37","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.3390\/cells11162511","volume":"11","author":"N Nasiri-Ansari","year":"2022","unstructured":"Nasiri-Ansari, N. et al. Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): A concise review. Cells 11(16), 2511 (2022).","journal-title":"Cells"},{"issue":"1","key":"66287_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coi.2005.11.007","volume":"18","author":"WK Born","year":"2006","unstructured":"Born, W. K., Reardon, C. L. & O\u2019Brien, R. L. The function of gammadelta T cells in innate immunity. Curr. Opin. Immunol. 18(1), 31\u201338 (2006).","journal-title":"Curr. Opin. Immunol."},{"issue":"7","key":"66287_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2781","volume":"10","author":"M Bonneville","year":"2010","unstructured":"Bonneville, M., O\u2019Brien, R. L. & Born, W. K. Gammadelta T cell effector functions: A blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10(7), 467\u2013478 (2010).","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"66287_CR40","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood-2009-07-234211","volume":"116","author":"A Maniar","year":"2010","unstructured":"Maniar, A. et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 116(10), 1726\u20131733 (2010).","journal-title":"Blood"},{"issue":"2","key":"66287_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2014.03.007","volume":"234","author":"HY Cheng","year":"2014","unstructured":"Cheng, H. Y., Wu, R. & Hedrick, C. C. Gammadelta (\u03b3\u03b4) T lymphocytes do not impact the development of early atherosclerosis. Atherosclerosis 234(2), 265\u2013269 (2014).","journal-title":"Atherosclerosis"},{"issue":"22","key":"66287_CR42","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1111\/bph.13845","volume":"174","author":"T Kyaw","year":"2017","unstructured":"Kyaw, T. et al. Cytotoxic lymphocytes and atherosclerosis: Significance, mechanisms and therapeutic challenges. Br. J. Pharmacol. 174(22), 3956\u20133972 (2017).","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"66287_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109416","volume":"9","author":"DM Vu","year":"2014","unstructured":"Vu, D. M. et al. \u03b3\u03b4T cells are prevalent in the proximal aorta and drive nascent atherosclerotic lesion progression and neutrophilia in hypercholesterolemic mice. PLoS\u00a0One 9(10), e109416 (2014).","journal-title":"PLoS\u00a0One"},{"issue":"2 Suppl 1","key":"66287_CR44","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1002\/hep.21060","volume":"43","author":"V Racanelli","year":"2006","unstructured":"Racanelli, V. & Rehermann, B. The liver as an immunological organ. Hepatology 43(2 Suppl 1), S54\u2013S62 (2006).","journal-title":"Hepatology"},{"issue":"2","key":"66287_CR45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/hep.26697","volume":"59","author":"L Hammerich","year":"2014","unstructured":"Hammerich, L. et al. Chemokine receptor CCR6-dependent accumulation of \u03b3\u03b4 T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 59(2), 630\u2013642 (2014).","journal-title":"Hepatology"},{"issue":"2","key":"66287_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4291\/wjgp.v5.i2.107","volume":"5","author":"L Hammerich","year":"2014","unstructured":"Hammerich, L. & Tacke, F. Role of gamma-delta T cells in liver inflammation and fibrosis. World J. Gastrointest. Pathophysiol. 5(2), 107\u2013113 (2014).","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"66287_CR47","doi-asserted-by":"publisher","first-page":"13839","DOI":"10.1038\/ncomms13839","volume":"7","author":"F Li","year":"2017","unstructured":"Li, F. et al. The microbiota maintain homeostasis of liver-resident \u03b3\u03b4T-17 cells in a lipid antigen\/CD1d-dependent manner. Nat. Commun. 7, 13839 (2017).","journal-title":"Nat. Commun."},{"issue":"2","key":"66287_CR48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/hep.30952","volume":"71","author":"A Torres-Hernandez","year":"2020","unstructured":"Torres-Hernandez, A. et al. \u03b3\u03b4 T cells promote steatohepatitis by orchestrating innate and adaptive immune programming. Hepatology 71(2), 477\u2013494 (2020).","journal-title":"Hepatology"},{"key":"66287_CR49","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3389\/fimmu.2020.01500","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen, Y. & Tian, Z. Roles of hepatic innate and innate-like lymphocytes in nonalcoholic steatohepatitis. Front. Immunol. 11, 1500 (2020).","journal-title":"Front. Immunol."},{"issue":"2","key":"66287_CR50","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/hep.31025","volume":"71","author":"X Wang","year":"2020","unstructured":"Wang, X. & Gao, B. \u03b3\u03b4T cells and CD1d, novel immune players in alcoholic and nonalcoholic steatohepatitis?. Hepatology 71(2), 408\u2013410 (2020).","journal-title":"Hepatology"},{"issue":"2","key":"66287_CR51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2011.08.041","volume":"220","author":"V Bieghs","year":"2012","unstructured":"Bieghs, V., Rensen, P. C., Hofker, M. H. & Shiri-Sverdlov, R. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis 220(2), 287\u2013293 (2012).","journal-title":"Atherosclerosis"},{"issue":"3","key":"66287_CR52","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bph.12490","volume":"171","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br. J. Pharmacol. 171(3), 723\u2013734 (2014).","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"66287_CR53","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/MEG.0000000000002392","volume":"34","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: A matched case-control study. Eur. J. Gastroenterol. Hepatol. 34(8), 838\u2013843 (2022).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3\u20134","key":"66287_CR54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000519906","volume":"9","author":"SK Kunutsor","year":"2021","unstructured":"Kunutsor, S. K., Dey, R. S. & Laukkanen, J. A. Circulating serum copper is associated with atherosclerotic cardiovascular disease, but not venous thromboembolism: A prospective cohort study. Pulse (Basel) 9(3\u20134), 109\u2013115 (2021).","journal-title":"Pulse (Basel)"},{"key":"66287_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114830","volume":"163","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease. Biomed. Pharmacother. 163, 114830 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"66287_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2021.112295","volume":"218","author":"C Chen","year":"2021","unstructured":"Chen, C. et al. Copper exposure association with prevalence of non-alcoholic fatty liver disease and insulin resistance among US adults (NHANES 2011\u20132014). Ecotoxicol. Environ. Saf. 218, 112295 (2021).","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"11","key":"66287_CR57","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S0891-5849(01)00649-9","volume":"31","author":"C Mazi\u00e8re","year":"2001","unstructured":"Mazi\u00e8re, C., Conte, M. A. & Mazi\u00e8re, J. C. Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein. Free Radic. Biol. Med. 31(11), 1334\u20131340 (2001).","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"66287_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac358","volume":"23","author":"L Huang","year":"2022","unstructured":"Huang, L., Zhang, L. & Chen, X. Updated review of advances in microRNAs and complex diseases: Taxonomy, trends and challenges of computational models. Brief. Bioinform. 23(5), bbac358 (2022).","journal-title":"Brief. Bioinform."},{"issue":"6","key":"66287_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac407","volume":"23","author":"L Huang","year":"2022","unstructured":"Huang, L., Zhang, L. & Chen, X. Updated review of advances in microRNAs and complex diseases: Towards systematic evaluation of computational models. Brief. Bioinform. 23(6), bbac407 (2022).","journal-title":"Brief. Bioinform."},{"issue":"1","key":"66287_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17460441.2019.1549033","volume":"14","author":"VG Maltarollo","year":"2019","unstructured":"Maltarollo, V. G., Kronenberger, T., Espinoza, G. Z., Oliveira, P. R. & Honorio, K. M. Advances with support vector machines for novel drug discovery. Expert Opin. Drug Discov. 14(1), 23\u201333 (2019).","journal-title":"Expert Opin. Drug Discov."},{"issue":"4","key":"66287_CR61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/MCA.0000000000000236","volume":"26","author":"HT Yu","year":"2015","unstructured":"Yu, H. T. et al. Serum monokine induced by gamma interferon as a novel biomarker for coronary artery calcification in humans. Coron. Artery Dis. 26(4), 317\u2013321 (2015).","journal-title":"Coron. Artery Dis."},{"issue":"8","key":"66287_CR62","doi-asserted-by":"publisher","first-page":"816","DOI":"10.5551\/jat.28886","volume":"22","author":"HT Yu","year":"2015","unstructured":"Yu, H. T., Lee, J., Shin, E. C. & Park, S. Significant association between serum monokine induced by gamma interferon and carotid intima media thickness. J. Atheroscler. Thromb. 22(8), 816\u2013822 (2015).","journal-title":"J. Atheroscler. Thromb."},{"issue":"1","key":"66287_CR63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1536\/ihj.15-472","volume":"58","author":"Y Liang","year":"2017","unstructured":"Liang, Y. et al. Serum monokine induced by gamma interferon is associated with severity of coronary artery disease. Int. Heart J. 58(1), 24\u201329 (2017).","journal-title":"Int. Heart J."},{"issue":"6","key":"66287_CR64","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1189\/jlb.1102573","volume":"73","author":"JH Xie","year":"2003","unstructured":"Xie, J. H. et al. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J. Leukoc. Biol. 73(6), 771\u2013780 (2003).","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"66287_CR65","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2249.2005.02850.x","volume":"141","author":"T Tsubaki","year":"2005","unstructured":"Tsubaki, T. et al. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig\/CXCL9 by synovial fibroblasts. Clin. Exp. Immunol. 141(2), 363\u2013371 (2005).","journal-title":"Clin. Exp. Immunol."},{"key":"66287_CR66","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s11154-023-09800-w","volume":"24","author":"A Ullah","year":"2023","unstructured":"Ullah, A. et al. A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease. Rev. Endocr. Metab. Disord. 24, 611\u2013631 (2023).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"66287_CR67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-230X-13-120","volume":"13","author":"T Semba","year":"2013","unstructured":"Semba, T. et al. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol. 13, 120 (2013).","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"66287_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112801","volume":"407","author":"L Li","year":"2021","unstructured":"Li, L. et al. MIG\/CXCL9 exacerbates the progression of metabolic-associated fatty liver disease by disrupting Treg\/Th17 balance. Exp. Cell Res. 407(2), 112801 (2021).","journal-title":"Exp. Cell Res."},{"issue":"1","key":"66287_CR69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12906-019-2577-6","volume":"19","author":"M Zhu","year":"2019","unstructured":"Zhu, M. et al. Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRNA\/circRNA immune ceRNA networks. BMC Complement. Altern. Med. 19(1), 156 (2019).","journal-title":"BMC Complement. Altern. Med."},{"key":"66287_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.862278","volume":"9","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. SPP1 and CXCL9 promote non-alcoholic steatohepatitis progression based on bioinformatics analysis and experimental studies. Front. Med. (Lausanne) 9, 862278 (2022).","journal-title":"Front. Med. (Lausanne)"},{"issue":"4","key":"66287_CR71","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1161\/ATVBAHA.119.312287","volume":"40","author":"TX Zhao","year":"2020","unstructured":"Zhao, T. X., Newland, S. A. & Mallat, Z. 2019 ATVB plenary lecture: Interleukin-2 therapy in cardiovascular disease: The potential to regulate innate and adaptive immunity. Arterioscler. Thromb. Vasc. Biol. 40(4), 853\u2013864 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"66287_CR72","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1007\/s11033-021-06483-x","volume":"48","author":"R Kuan","year":"2021","unstructured":"Kuan, R., Agrawal, D. K. & Thankam, F. G. Treg cells in atherosclerosis. Mol. Biol. Rep. 48(5), 4897\u20134910 (2021).","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"66287_CR73","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.119.316461","volume":"127","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ. Res. 127(3), 335\u2013353 (2020).","journal-title":"Circ. Res."},{"issue":"8","key":"66287_CR74","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/aps.2017.140","volume":"39","author":"HX Ou","year":"2018","unstructured":"Ou, H. X. et al. Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharmacol. Sin. 39(8), 1249\u20131258 (2018).","journal-title":"Acta Pharmacol. Sin."},{"issue":"27","key":"66287_CR75","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3748\/wjg.v28.i27.3346","volume":"28","author":"CY Zhang","year":"2022","unstructured":"Zhang, C. Y., Liu, S. & Yang, M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J. Gastroenterol. 28(27), 3346\u20133358 (2022).","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"66287_CR76","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/hep4.1807","volume":"6","author":"J Dywicki","year":"2022","unstructured":"Dywicki, J. et al. The detrimental role of regulatory T cells in nonalcoholic steatohepatitis. Hepatol. Commun. 6(2), 320\u2013333 (2022).","journal-title":"Hepatol. Commun."},{"issue":"3","key":"66287_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/aei.v51i3.757","volume":"51","author":"J Zhou","year":"2023","unstructured":"Zhou, J., Zhang, Y. & Zhuang, Q. IL2RB affects Th1\/Th2 and Th17 responses of peripheral blood mononuclear cells from septic patients. Allergol. Immunopathol. (Madr) 51(3), 1\u20137 (2023).","journal-title":"Allergol. Immunopathol. (Madr)"},{"issue":"2","key":"66287_CR78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96600","volume":"3","author":"X Yuan","year":"2018","unstructured":"Yuan, X., Dong, Y., Tsurushita, N., Tso, J. Y. & Fu, W. CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms. JCI Insight 3(2), e96600 (2018).","journal-title":"JCI Insight"},{"key":"66287_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.04.010","volume":"326","author":"M Mulholland","year":"2021","unstructured":"Mulholland, M. et al. IL-2R\u03b2\u03b3 signalling in lymphocytes promotes systemic inflammation and reduces plasma cholesterol in atherosclerotic mice. Atherosclerosis 326, 1\u201310 (2021).","journal-title":"Atherosclerosis"},{"issue":"11","key":"66287_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113724","volume":"9","author":"J Xia","year":"2014","unstructured":"Xia, J. et al. Transcriptome analysis on the inflammatory cell infiltration of nonalcoholic steatohepatitis in bama minipigs induced by a long-term high-fat, high-sucrose diet. PLoS\u00a0One 9(11), e113724 (2014).","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"66287_CR81","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.atherosclerosis.2014.07.004","volume":"236","author":"T Wolak","year":"2014","unstructured":"Wolak, T. Osteopontin\u2014A multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis 236(2), 327\u2013337 (2014).","journal-title":"Atherosclerosis"},{"issue":"10","key":"66287_CR82","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/01.ATV.14.10.1648","volume":"14","author":"ER O'Brien","year":"1994","unstructured":"O\u2019Brien, E. R. et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler. Thromb. 14(10), 1648\u20131656 (1994).","journal-title":"Arterioscler. Thromb."},{"issue":"2","key":"66287_CR83","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0021-9150(03)00298-3","volume":"170","author":"R Ohmori","year":"2003","unstructured":"Ohmori, R. et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170(2), 333\u2013337 (2003).","journal-title":"Atherosclerosis"},{"issue":"2","key":"66287_CR84","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.atherosclerosis.2009.12.024","volume":"210","author":"Y Momiyama","year":"2010","unstructured":"Momiyama, Y. et al. Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Atherosclerosis 210(2), 668\u2013670 (2010).","journal-title":"Atherosclerosis"},{"issue":"5","key":"66287_CR85","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/01.CIR.0000055739.13639.D7","volume":"107","author":"K Isoda","year":"2003","unstructured":"Isoda, K. et al. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 107(5), 679\u2013681 (2003).","journal-title":"Circulation"},{"issue":"1","key":"66287_CR86","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/jcp.22709","volume":"227","author":"YH Zheng","year":"2012","unstructured":"Zheng, Y. H. et al. Osteopontin stimulates autophagy via integrin\/CD44 and p38 MAPK signaling pathways in vascular smooth muscle cells. J. Cell. Physiol. 227(1), 127\u2013135 (2012).","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"66287_CR87","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12041-016-0673-7","volume":"95","author":"G Wang","year":"2016","unstructured":"Wang, G. et al. Comparative analysis of gene expression profiles of OPN signaling pathway in four kinds of liver diseases. J. Genet. 95(3), 741\u2013750 (2016).","journal-title":"J. Genet."},{"issue":"1","key":"66287_CR88","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.dld.2012.08.017","volume":"45","author":"Y Yilmaz","year":"2013","unstructured":"Yilmaz, Y. et al. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig. Liver Dis. 45(1), 58\u201362 (2013).","journal-title":"Dig. Liver Dis."},{"key":"66287_CR89","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.nut.2018.12.001","volume":"62","author":"BM Arendt","year":"2019","unstructured":"Arendt, B. M. et al. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease. Nutrition 62, 100\u2013107 (2019).","journal-title":"Nutrition"},{"issue":"1","key":"66287_CR90","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41598-022-04971-z","volume":"12","author":"LV Herrera-Marcos","year":"2022","unstructured":"Herrera-Marcos, L. V. et al. Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model. Sci. Rep. 12(1), 1024 (2022).","journal-title":"Sci. Rep."},{"issue":"7","key":"66287_CR91","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1111\/liv.14464","volume":"40","author":"AD Nardo","year":"2020","unstructured":"Nardo, A. D. et al. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. Liver Int. 40(7), 1620\u20131633 (2020).","journal-title":"Liver Int."},{"issue":"1","key":"66287_CR92","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/cvr\/cvn007","volume":"78","author":"TT Tuomisto","year":"2008","unstructured":"Tuomisto, T. T. et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc. Res. 78(1), 175\u2013184 (2008).","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"66287_CR93","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12931-016-0424-6","volume":"17","author":"K Maneechotesuwan","year":"2016","unstructured":"Maneechotesuwan, K., Kasetsinsombat, K., Wongkajornsilp, A. & Barnes, P. J. Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism. Respir. Res. 17(1), 104 (2016).","journal-title":"Respir. Res."},{"issue":"1","key":"66287_CR94","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jvs.2009.07.119","volume":"51","author":"NP Kadoglou","year":"2010","unstructured":"Kadoglou, N. P. et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J. Vasc. Surg. 51(1), 114\u2013121 (2010).","journal-title":"J. Vasc. Surg."},{"issue":"6","key":"66287_CR95","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2310\/6650.2005.53610","volume":"53","author":"J Goebel","year":"2005","unstructured":"Goebel, J. et al. Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor beta chain. J. Investig. Med. 53(6), 322\u2013328 (2005).","journal-title":"J. Investig. Med."},{"issue":"8","key":"66287_CR96","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/0961203310364400","volume":"19","author":"GA Ferreira","year":"2010","unstructured":"Ferreira, G. A., Teixeira, A. L. & Sato, E. I. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 19(8), 927\u2013934 (2010).","journal-title":"Lupus"},{"issue":"1","key":"66287_CR97","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1210\/endo.135.1.8013390","volume":"135","author":"H Kaji","year":"1994","unstructured":"Kaji, H. et al. Calcitonin inhibits osteopontin mRNA expression in isolated rabbit osteoclasts. Endocrinology 135(1), 484\u2013487 (1994).","journal-title":"Endocrinology"},{"issue":"4","key":"66287_CR98","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1159\/000087438","volume":"101","author":"A Khanna","year":"2005","unstructured":"Khanna, A. Tacrolimus and cyclosporinein vitro and in vivo induce osteopontin mRNA and protein expression in renal tissues. Nephron Exp. Nephrol. 101(4), e119\u2013e126 (2005).","journal-title":"Nephron Exp. Nephrol."},{"issue":"3","key":"66287_CR99","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s00223-018-0501-6","volume":"104","author":"Z Weng","year":"2019","unstructured":"Weng, Z. et al. All-trans retinoic acid promotes osteogenic differentiation and bone consolidation in a rat distraction osteogenesis model. Calcif. Tissue Int. 104(3), 320\u2013330 (2019).","journal-title":"Calcif. Tissue Int."},{"issue":"12","key":"66287_CR100","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1002\/dvdy.22154","volume":"238","author":"DS Peal","year":"2009","unstructured":"Peal, D. S., Burns, C. G., Macrae, C. A. & Milan, D. Chondroitin sulfate expression is required for cardiac atrioventricular canal formation. Dev. Dyn. 238(12), 3103\u20133110 (2009).","journal-title":"Dev. Dyn."},{"issue":"2","key":"66287_CR101","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-015-2847-x","volume":"24","author":"G Mergoni","year":"2016","unstructured":"Mergoni, G. et al. The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone. Support. Care Cancer 24(2), 807\u2013813 (2016).","journal-title":"Support. Care Cancer"},{"issue":"6","key":"66287_CR102","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijom.2011.02.002","volume":"40","author":"J Katz","year":"2011","unstructured":"Katz, J. et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int. J. Oral Maxillofac. Surg. 40(6), 605\u2013611 (2011).","journal-title":"Int. J. Oral Maxillofac. Surg."},{"issue":"22","key":"66287_CR103","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/0006-2952(77)90264-7","volume":"26","author":"L Robert","year":"1977","unstructured":"Robert, L., Brechemier, D., Godeau, G., Labat, M. L. & Milhaud, G. Prevention of experimental immunarteriosclerosis by calcitonin. Biochem. Pharmacol. 26(22), 2129\u20132135 (1977).","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"66287_CR104","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1172\/JCI113713","volume":"82","author":"Y Nishizawa","year":"1988","unstructured":"Nishizawa, Y. et al. Calcium\/calmodulin-mediated action of calcitonin on lipid metabolism in rats. J. Clin. Investig. 82(4), 1165\u20131172 (1988).","journal-title":"J. Clin. Investig."},{"issue":"3","key":"66287_CR105","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0014-4800(87)90055-4","volume":"46","author":"MP Jacob","year":"1987","unstructured":"Jacob, M. P. et al. Prevention by calcitonin of the pathological modifications of the rabbit arterial wall induced by immunization with elastin peptides: Effect on vascular smooth muscle permeability to ions. Exp. Mol. Pathol. 46(3), 345\u2013356 (1987).","journal-title":"Exp. Mol. Pathol."},{"key":"66287_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.617400","volume":"11","author":"DS Mathiesen","year":"2020","unstructured":"Mathiesen, D. S., Lund, A., Vilsb\u00f8ll, T., Knop, F. K. & Bagger, J. I. Amylin and calcitonin: Potential therapeutic strategies to reduce body weight and liver fat. Front. Endocrinol. (Lausanne) 11, 617400 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"66287_CR107","first-page":"1393","volume":"19","author":"X Li","year":"2020","unstructured":"Li, X., Shang, X. & Sun, L. Tacrolimus reduces atherosclerotic plaque formation in ApoE(\u2212\/\u2212) mice by inhibiting NLRP3 inflammatory corpuscles. Exp. Ther. Med. 19(2), 1393\u20131399 (2020).","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"66287_CR108","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2009.07.040","volume":"208","author":"N Hamada","year":"2010","unstructured":"Hamada, N. et al. Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin\/NFAT signaling in porcine coronary artery model. Atherosclerosis 208(1), 97\u2013103 (2010).","journal-title":"Atherosclerosis"},{"issue":"69","key":"66287_CR109","doi-asserted-by":"publisher","first-page":"113403","DOI":"10.18632\/oncotarget.15194","volume":"8","author":"S Love","year":"2017","unstructured":"Love, S., Mudasir, M. A., Bhardwaj, S. C., Singh, G. & Tasduq, S. A. Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL\/6J mice by inhibiting de-novo lipogenesis. Oncotarget 8(69), 113403\u2013113417 (2017).","journal-title":"Oncotarget"},{"issue":"7","key":"66287_CR110","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/biom12070869","volume":"12","author":"Q Deng","year":"2022","unstructured":"Deng, Q. & Chen, J. Potential therapeutic effect of all-trans retinoic acid on atherosclerosis. Biomolecules 12(7), 869 (2022).","journal-title":"Biomolecules"},{"issue":"1","key":"66287_CR111","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3945\/ajcn.114.105155","volume":"102","author":"Y Liu","year":"2015","unstructured":"Liu, Y. et al. Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 102(1), 130\u2013137 (2015).","journal-title":"Am. J. Clin. Nutr."},{"issue":"11","key":"66287_CR112","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s11427-016-9027-6","volume":"60","author":"C Geng","year":"2017","unstructured":"Geng, C. et al. Retinoic acid ameliorates high-fat diet-induced liver steatosis through sirt1. Sci. China Life Sci. 60(11), 1234\u20131241 (2017).","journal-title":"Sci. China Life Sci."},{"issue":"10","key":"66287_CR113","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1532-5415.1969.tb02328.x","volume":"17","author":"LM Morrison","year":"1969","unstructured":"Morrison, L. M. Response of ischemic heart disease to chondroitin sulfate-A. J. Am. Geriatr. Soc. 17(10), 913\u2013923 (1969).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"5","key":"66287_CR114","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/000331977302400503","volume":"24","author":"LM Morrison","year":"1973","unstructured":"Morrison, L. M. & Enrick, N. Coronary heart disease: Reduction of death rate by chondroitin sulfate A. Angiology 24(5), 269\u2013287 (1973).","journal-title":"Angiology"},{"issue":"2","key":"66287_CR115","first-page":"153","volume":"34","author":"K Nakazawa","year":"1979","unstructured":"Nakazawa, K. & Murata, K. Comparative study of the effects of chondroitin sulfate isomers on atherosclerotic subjects. Z. Alternsforsch. 34(2), 153\u2013159 (1979).","journal-title":"Z. Alternsforsch."},{"issue":"4","key":"66287_CR116","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/bjp.2008.113","volume":"154","author":"G Herrero-Beaumont","year":"2008","unstructured":"Herrero-Beaumont, G. et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br. J. Pharmacol. 154(4), 843\u2013851 (2008).","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"66287_CR117","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1055\/s-0038-1657753","volume":"118","author":"P Melgar-Lesmes","year":"2018","unstructured":"Melgar-Lesmes, P. et al. Chondroitin sulphate attenuates atherosclerosis in ApoE knockout mice involving cellular regulation of the inflammatory response. Thromb. Haemost. 118(7), 1329\u20131339 (2018).","journal-title":"Thromb. Haemost."},{"key":"66287_CR118","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2015.12.016","volume":"245","author":"P Melgar-Lesmes","year":"2016","unstructured":"Melgar-Lesmes, P. et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis 245, 82\u201387 (2016).","journal-title":"Atherosclerosis"},{"key":"66287_CR119","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ijbiomac.2022.05.195","volume":"213","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Chondroitin sulfate stimulates the secretion of H(2)S by Desulfovibrio to improve insulin sensitivity in NAFLD mice. Int. J. Biol. Macromol. 213, 631\u2013638 (2022).","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"66287_CR120","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00223-008-9123-8","volume":"82","author":"A Gozzetti","year":"2008","unstructured":"Gozzetti, A. et al. The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif. Tissue Int. 82(4), 258\u2013262 (2008).","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"66287_CR121","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11914-020-00612-4","volume":"18","author":"EO Billington","year":"2020","unstructured":"Billington, E. O. & Reid, I. R. Benefits of bisphosphonate therapy: Beyond the skeleton. Curr. Osteoporos. Rep. 18(5), 587\u2013596 (2020).","journal-title":"Curr. Osteoporos. Rep."},{"issue":"1","key":"66287_CR122","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejphar.2008.10.043","volume":"602","author":"L Wu","year":"2009","unstructured":"Wu, L. et al. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur. J. Pharmacol. 602(1), 124\u2013131 (2009).","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"66287_CR123","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3390\/pharmaceutics14061262","volume":"14","author":"E Lo Presti","year":"2022","unstructured":"Lo Presti, E., D\u2019Orsi, L. & De Gaetano, A. A mathematical model of in vitro cellular uptake of zoledronic acid and isopentenyl pyrophosphate accumulation. Pharmaceutics 14(6), 1262 (2022).","journal-title":"Pharmaceutics"},{"key":"66287_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172469","volume":"858","author":"RH Mohamed","year":"2019","unstructured":"Mohamed, R. H., Tarek, M., Hamam, G. G. & Ezzat, S. F. Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; The potential role of mevalonic acid pathway in nonalcoholic steatohepatitis. Eur. J. Pharmacol. 858, 172469 (2019).","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"66287_CR125","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11883-013-0386-9","volume":"16","author":"H Toba","year":"2014","unstructured":"Toba, H., Cortez, D., Lindsey, M. L. & Chilton, R. J. Applications of miRNA technology for atherosclerosis. Curr. Atheroscler. Rep. 16(2), 386 (2014).","journal-title":"Curr. Atheroscler. Rep."},{"key":"66287_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101581","volume":"65","author":"MY Hochreuter","year":"2022","unstructured":"Hochreuter, M. Y., Dall, M., Treebak, J. T. & Barr\u00e8s, R. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol. Metab. 65, 101581 (2022).","journal-title":"Mol. Metab."},{"issue":"6\u20137","key":"66287_CR127","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/15384101.2019.1580493","volume":"18","author":"M Fang","year":"2019","unstructured":"Fang, M. et al. miR-185 silencing promotes the progression of atherosclerosis via targeting stromal interaction molecule 1. Cell Cycle 18(6\u20137), 682\u2013695 (2019).","journal-title":"Cell Cycle"},{"issue":"4","key":"66287_CR128","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.18632\/aging.203896","volume":"14","author":"W Tan","year":"2022","unstructured":"Tan, W. et al. The elevation of miR-185-5p alleviates high-fat diet-induced atherosclerosis and lipid accumulation in vivo and in vitro via SREBP2 activation. Aging (Albany NY) 14(4), 1729\u20131742 (2022).","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"66287_CR129","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1194\/jlr.M041335","volume":"55","author":"M Yang","year":"2014","unstructured":"Yang, M. et al. Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J. Lipid Res. 55(2), 226\u2013238 (2014).","journal-title":"J. Lipid Res."},{"issue":"11","key":"66287_CR130","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1139\/cjpp-2020-0764","volume":"100","author":"X Xi","year":"2022","unstructured":"Xi, X., Zheng, X., Zhang, R. & Zeng, L. Upregulation of circFOXP1 attenuates inflammation and apoptosis induced by ox-LDL in human umbilical vein endothelial cells by regulating the miR-185-5p\/BCL-2 axis. Can. J. Physiol. Pharmacol. 100(11), 1045\u20131054 (2022).","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"47","key":"66287_CR131","doi-asserted-by":"publisher","first-page":"17914","DOI":"10.3748\/wjg.v20.i47.17914","volume":"20","author":"XC Wang","year":"2014","unstructured":"Wang, X. C., Zhan, X. R., Li, X. Y., Yu, J. J. & Liu, X. M. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease. World J. Gastroenterol. 20(47), 17914\u201317923 (2014).","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"66287_CR132","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23608","volume":"35","author":"D Sun","year":"2021","unstructured":"Sun, D., Ma, T., Zhang, Y., Zhang, F. & Cui, B. Overexpressed miR-335-5p reduces atherosclerotic vulnerable plaque formation in acute coronary syndrome. J. Clin. Lab. Anal. 35(2), e23608 (2021).","journal-title":"J. Clin. Lab. Anal."},{"issue":"5","key":"66287_CR133","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20211775","volume":"42","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. H2O2 down-regulates SIRT7\u2019s protective role of endothelial premature dysfunction via microRNA-335-5p. Biosci. Rep. 42(5), BSR20211775 (2022).","journal-title":"Biosci. Rep."},{"issue":"7","key":"66287_CR134","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3724\/abbs.2022081","volume":"54","author":"R Ma","year":"2022","unstructured":"Ma, R. et al. miR-335-5p regulates the proliferation, migration and phenotypic switching of vascular smooth muscle cells in aortic dissection by directly regulating SP1. Acta Biochim. Biophys. Sin. (Shanghai) 54(7), 961\u2013973 (2022).","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"issue":"2","key":"66287_CR135","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/apha.12681","volume":"219","author":"S Vienberg","year":"2017","unstructured":"Vienberg, S., Geiger, J., Madsen, S. & Dalgaard, L. T. MicroRNAs in metabolism. Acta Physiol. (Oxf.) 219(2), 346\u2013361 (2017).","journal-title":"Acta Physiol. (Oxf.)"},{"issue":"7","key":"66287_CR136","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s13258-021-01150-8","volume":"44","author":"JW Zhang","year":"2022","unstructured":"Zhang, J. W. & Pan, H. T. microRNA profiles of serum exosomes derived from children with nonalcoholic fatty liver. Genes Genomics 44(7), 879\u2013888 (2022).","journal-title":"Genes Genomics"},{"issue":"3","key":"66287_CR137","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.aohep.2019.12.003","volume":"19","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Identification and study of differentially expressed miRNAs in aged NAFLD rats based on high-throughput sequencing. Ann. Hepatol. 19(3), 302\u2013312 (2020).","journal-title":"Ann. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66287-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66287-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66287-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T06:13:40Z","timestamp":1721110420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66287-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66287"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-66287-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16364"}}